Method of treating eosinophilia by administering an immunomodulating peptide

Patent metadata

Field	Value
Publication number	US-9315544-B2
Application number	US-201314022795-A
Country	US
Kind code	B2
Filing date	Sep 10, 2013
Priority date	Sep 10, 2012
Publication date	Apr 19, 2016
Grant date	Apr 19, 2016

Abstract

A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided.

First claim

What is claimed is:

1. A method for treating eosinophilia in a subject in need thereof by downregulating CCL-11 expression in the subject, comprising administering to the subject a pharmaceutically effective composition of a peptide consisting of SEQ ID NO: 1.

2. The method of claim 1 , wherein administration is achieved by a route selected from inhalation, intranasal, aerosol, or intratracheal.

3. The method of claim 1 , wherein the eosinophilia is associated with asthma, bronchitis, allergic bronchitis, bronchial asthma, emphysema, chronic obstructive pulmonary disease, or lung fibrosis.

4. The method of claim 1 , wherein the composition reduces inflammation, leukocyte recruitment, chemokine levels or inflammatory cytokine levels in the subject.

5. The method of claim 4 , wherein the leukocyte is macrophage, basophil, neutrophil, eosinophil or lymphocyte.

6. The method of claim 4 , wherein the chemokine is CCL-26 or CXCL-12.

7. The method of claim 4 , wherein the inflammatory cytokine is IL-1β, IL-4, IL-5, IL-6, IL-8, IL-13 or IL-18.

8. The method of claim 1 , wherein the composition reduces severity of asthma attack, airway obstruction, bronchial spasms, airway hyperreactivity, histopathological inflammation score, goblet cells hyperplasia or IgE levels in the subject.

9. The method of claim 1 , wherein the composition decreases airway resistance in the subject.

10. The method of claim 1 , which further comprises administering an agent selected from the group consisting of steroids, anti-IgE antibodies, anti-IL-4 antibodies, anti-IL-5 antibodies, leukotriene inhibitors, lipoxygenase inhibitors, IL-13 antagonists, cytokine release inhibitors, anti-histamines and histamine release inhibitors.

11. The method of claim 1 , wherein the subject is mammal.

Assignees

• Nat Univ Tsing Hua

Inventors

• Chang Margaret Dah-Tsyr
• Fu Lin-Shien
• Fang Shun-Lung

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title